Persist-1: a phase III study of pacritinib (Pac) vs best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF)
Harrison, C Szoke, A Suvorov, A Egyed, M Prasad, R Mayer, J Jakucs, J Elinder, A Recher, C te Boekhorst, PA
Harrison, C
Szoke, A
Suvorov, A
Egyed, M
Prasad, R
Mayer, J
Jakucs, J
Elinder, A
Recher, C
te Boekhorst, PA
Citations
Altmetric:
Abstract
Description
Date
2015
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Persist-1: a phase III study of pacritinib (Pac) vs best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF). 2015, 100: 103 Haematologica